BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1283 related articles for article (PubMed ID: 28716106)

  • 1. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
    Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
    J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
    Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
    BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.
    Glutsch V; Grän F; Weber J; Gesierich A; Goebeler M; Schilling B
    J Immunother Cancer; 2019 Jul; 7(1):181. PubMed ID: 31300044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

  • 5. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor.
    Escandon J; Peacock S; Trabolsi A; Thomas DB; Layka A; Lutzky J
    J Immunother Cancer; 2017; 5():3. PubMed ID: 28105370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients.
    Shirali AC; Perazella MA; Gettinger S
    Am J Kidney Dis; 2016 Aug; 68(2):287-291. PubMed ID: 27113507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature.
    Tabei A; Watanabe M; Ikeuchi H; Nakasatomi M; Sakairi T; Kaneko Y; Maeshima A; Kaira K; Hirato J; Nojima Y; Hiromura K
    Intern Med; 2018 Nov; 57(21):3135-3139. PubMed ID: 29877267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
    Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
    Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
    BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.
    Tominaga K; Takeuchi K; Takakuma S; Sakamoto E; Hatanaka S; Kajimoto Y; Toda E; Terasaki Y; Kunugi S; Terasaki M; Shimizu A
    BMC Nephrol; 2023 Mar; 24(1):48. PubMed ID: 36894873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer.
    Nakatani Y; Kawakami H; Ichikawa M; Yamamoto S; Otsuka Y; Mashiko A; Takashima Y; Ito A; Nakagawa K; Arima S
    Invest New Drugs; 2018 Aug; 36(4):726-731. PubMed ID: 29623482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
    Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
    Alnabulsi R; Hussain A; DeAngelis D
    Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKI in Patients Receiving Immune Checkpoint Inhibitors.
    Perazella MA; Sprangers B
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1077-1079. PubMed ID: 31048326
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ; Shirai K
    J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis.
    Qualls D; Seethapathy H; Bates H; Tajmir S; Heidari P; Endres P; Reynolds K; Lawrence D; Sise M
    J Immunother Cancer; 2019 Dec; 7(1):356. PubMed ID: 31864416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
    Cortazar FB; Marrone KA; Troxell ML; Ralto KM; Hoenig MP; Brahmer JR; Le DT; Lipson EJ; Glezerman IG; Wolchok J; Cornell LD; Feldman P; Stokes MB; Zapata SA; Hodi FS; Ott PA; Yamashita M; Leaf DE
    Kidney Int; 2016 Sep; 90(3):638-47. PubMed ID: 27282937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature.
    Saiki R; Katayama K; Saiki H; Fukumori A; Tsujimoto K; Yamawaki M; Tanaka F; Takahashi D; Oda K; Suzuki Y; Murata T; Dohi K
    BMC Nephrol; 2024 Feb; 25(1):51. PubMed ID: 38336610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.